JuniperPublishers-Pancreatic Carcinoma: An Overview

Journal of Surgery- JuniperPublishers

Editorial

Pancreatic cancer is the 12th most common cancer in the world. The estimated 5-year prevalence of people in the world living with pancreatic cancer is 4.1 per 100,000. The average lifetime risk of developing a pancreatic carcinoma for both men and women is 1.5%. The number of new cases of pancreatic cancer is 12.4 per 100,000 men and women per year and the number of deaths is 10.9 per 100,000 men and women per year, making it one of the most deadly solid organ tumors of the body [1,2]. Pancreatic ductal adenocarcinoma is by far the most common histologic subtype of pancreatic carcinoma, regardless of the location within pancreas. Other rare histological subtypes include acinar, squamous, pancreatic endocrine neoplasms or tumors of non-epithelial origin [3].
The various proven risk factors for the development of Pancreatic cancer include cigarette smoking (current> past), Diabetes Mellitus, Obesity, Heavy alcohol intake, Chronic Pancreatitis [4]. 10% of all the pancreatic cancers are hereditary, mostly being associated with syndromes like HNPCC (Hereditary Non Polyposis Colorectal Cancer), Familial Breast cancer associated with BRCA2 mutation, Peutz-Jeghers syndrome, Ataxia-telangiectasia syndrome etc [5]. With recent genetic improvements, kRAS has been identified to be the most common associated genetic abnormality (>95%). The other commonly associated genetic alterations include p53, p16 and DPC4 [6].
About 66 - 75% of patients present with symptoms of obstructive jaundice. Patients with pancreatic carcinoma may also present with pain in upper abdomen/epigastrium/back, anorexia, fatigue, and malaise and weight loss. Patients may also present with features of acute pancreatitis or Gastric outlet obstruction. Unusually present with new-onset Diabetes Mellitus or Anemia from Gastrointestinal blood loss. Palpable nodules in liver, left supraclavicular fossa, periumbilical fossa and pelvis are indicators of advanced disease. CT scan is the single most useful diagnostic and staging modality of choice [7]. It gives very important information aboutintrahepatic & extra-hepatic ductal dilatation, relationship of tumor with surrounding structures (Celiac axis, Hepatic artery, SMA and PV-SMV confluence) and any lymphadenopathy. 3D- reconstruction of CT has added to the ability of predicting the resectability of the pancreatic tumors. Tissue diagnosis isn’t required prior to an attempt at curative resection, but is necessary prior to neoadjuvant chemotherapy [8].
Patients with mass lesion in CT scan with no evidence of metastasis are primarily candidates for multi-disciplinary approach including surgical intervention, neoadjuvant and adjuvant chemo-radiotherapy with curative intent. Patients with pre-operative jaundice need to be evaluated for any features of cholangitis, as presence of cholangitis mandates re-operative biliary decompression (ERCP guided stenting of CBD). Patients with resectable growth on CT (Normal tissue plane between tumor and all 3 surrounding arteries i.e. SMA, Celiac axis and Common Hepatic Artery, and patent SMV-PV confluence) are primary candidates for Pancreatico-duodenectomy (Whipple procedure). Patients with borderline resectable growth on CT (<50% circumferential encasement of any 1 of 3 surrounding arteries i.e. SMA, Celiac axis and Common Hepatic Artery, or short segment occlusion of SMV-PV with possible reconstruction) are primarily biopsied using EUS guidance and then followed by neoadjuvant chemotherapy.
Multiple neoadjuvant chemoradiation regimens have been used with variable results. Gemcitabine 30 Gy regimen has had significantly better resection rate, partial response rate and median survival. Patients are then re-staged using CT and again evaluated for resectability. If the tumor is resectable post neo-adjuvant chemoradiation, patients undergo Whipple procedure. However, if the tumor remains still unresectable, the patients are treated as having unresectable tumors. Patients with unresectable tumors on CT (>50% circumferential encasement of any 1 of 3 surrounding arteries i.e. SMA, Celiac axis and Common Hepatic Artery, or occlusion of SMV-PV with no possible reconstruction) need multidisciplinary approach with palliative intent [9]. Patients with jaundice may be offered ERCP-stenting, hepaticojejunostomy, cholecystojejunostomy.
Patients with duodenal outlet obstruction may be palliated with Gastrojejunostomy, expandable metallic bowel sounds and those with pain may be palliated by opioids, NSAIDs, USG/CT-guided celiac plexus blocks, intra-operative chemical splanchnicectomy [4,8]. Various adjuvant therapies have been tried with drugs like 5-flourouracil, Gemcitabine etc. Gemcitabine has been proven to increase median disease free survival from 6.9 to 13.4 months [10]. Many novel agents like Bevacizumab (Angiogenesis inhibitor), Tipifarnib (kRAS inhibitors), Erlotinib (EGFR inhibitor) have been tried with varied success [8]. Finally at the end, even after so many technological advances, the tumorspecific 5 year survival rates are only 15% for patients with pancreatic carcinoma. Factors affecting survival of pancreatic carcinoma include tumor size of >3cm, positive resection margin, histological grade and regional lymph node metastases [11].

To read more articles in Journal of Surgery 

Comments

Post a Comment

Popular posts from this blog

Juniper Publishers| The Anatomical Architecture of the Junction between the Great Cerebral Vein and the Straight Sinus in Correlation to the Physiological and Biochemical Impact on Multiple Sclerosis Subtypes and Disease Progression- A Review Article

Image
  Journal of Surgery -  JuniperPublishers Abstract Introduction:  Multiple Sclerosis (MS) is a debilitating autoimmune disorder, characterized by damage to the white matter of the central nervous system. Studies suggest a relationship between impaired cerebral venous blood flow and progressive destruction of white matter in the CNS. Altered cerebral venous architecture is a possible mechanism that may contribute to a compromised venous blood flow pattern in MS patients. Natural variations at junction located between the great cerebral vein (GCV) and the straight sinus (Ss) located within the cerebral venous drainage system can potentially exacerbate MS progression. Recent data indicates that abnormal cerebral venous hemodynamics contributes to the pathophysiology observed in MS through an unknown mechanism that increases hydraulic resistance. Objective:  This review aims to investigate if anatomical variations at the GSV and Ss junction elicit a profound effect on the cerebral venous s
Read more

Juniper Publishers| The Use of the Second-Generation Protein Kinase Inhibitors in Patients with Gastrointestinal Stromal Tumor with Failure to the Treatment with Imatinib

  Journal of Surgery -  JuniperPublishers Introduction:  Gastrointestinal Stromal Tumor (GIST) is considered the most common mesenchymal tumor of the gastrointestinal tract. Approximately 85% of GISTs have mutations in proto-oncogene KIT encoding, a tyrosine kinase receptor. About 8% of GISTs are associated to mutations in the growth factor receptor alpha (PDGFRA) gene. The standard treatment of GIST is the surgical resection of the tumor. In cases of metastasis and tumor recurrence specific drugs as tyrosine kinase inhibitors are used. The first line treatment is Imatinib. Although the treatment with imatinib failed in some patients for the metastatic and relapsed treatment of GIST, the patients can to use other drugs, called second generation. Discussion:  One of the great advances in the diagnosis of GIST was the recognition through the immunohistochemistry of the c-Kit marker. The tyrosine kinase inhibitor, imatinib, has become the standard treatment for those, with high-risk resec
Read more